Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 26 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

12%

3 trials in Phase 3/4

Results Transparency

9%

1 of 11 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (3)
P 2 (10)
P 3 (1)
P 4 (2)

Trial Status

Completed11
Unknown7
Recruiting6
Not Yet Recruiting2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (26)

Showing 20 of 20 trials
NCT06223568Phase 2Recruiting

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

NCT04478838Phase 4Recruiting

"Extended" (Alternate Day) Antipsychotic Dosing

NCT06983080Phase 2Recruiting

Efficacy of Trazodone to Treat Insomnia in Older Adults (TRADITION Study)

NCT07113574Phase 2Completed

Pharmacokinetics of Meropenem and Aztreonam After Intraperitoneal Administration Via Cycler-therapy in APD Patients Without Peritonitis

NCT07090980Not ApplicableCompleted

Effects of Podcast Education on Medication Perception, Stigma Level, and Epilepsy Self-management in Epilepsy Patients

NCT04095104Phase 2Completed

Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds

NCT05322967Not ApplicableRecruiting

Effect of Chronotherapy on Blood Pressure - Time of Intake of Blood Pressure Lowering Drugs

NCT06539559Phase 2Not Yet Recruiting

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

NCT06485713Phase 2Recruiting

Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC

NCT04493905Completed

Effects of Anesthetic Techniques on Time to Start of Adjuvant Chemotherapy Following Surgery for Colorectal Cancer

NCT06009965Phase 4Unknown

Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System

NCT05366621Completed

Post-fracture Medication and Mortality

NCT03551457Completed

Potential Therapeutic Response In Urogenital Tumors

NCT04141657CompletedPrimary

Safety Analysis of Antimicrobial Pharmacotherapy in Intensive Care Unit at Pediatric Hospital

NCT05246722Unknown

Registry Study of Pharmacotherapy and Clinical Outcomes in Elderly Patients With Coronary Heart Disease (PHARM-ageing)

NCT04996732Recruiting

Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Single-institutional Cancer Registry

NCT03815487Not ApplicableCompleted

Comparison of Two Management Systems in Patients With Type 1 Diabetes (Pediatric SmartHome)

NCT03484195Phase 2Unknown

Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer

NCT03487939Phase 2Unknown

Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer

NCT03484221Phase 2Unknown

Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer

Scroll to load more

Research Network

Activity Timeline